Endoscopic retrograde cholangiopancreatography in the elderly.
BACKGROUND
Endoscopic retrograde cholangiopancreatography (ERCP) is a widely used technique for the diagnosis and treatment of biliary and pancreatic diseases.


OBJECTIVE
To know the complication rate of ERCP in the elderly.


METHODS
Patient files who underwent ERCP were reviewed and were divided into two groups: aged 65 and older (group 1) and less than 65 years (group 2). Socio-demographic variables, prophylactic antibiotic use, indications for ERCP and outcomes were assessed.


RESULTS
Mean age in group 1 was 72.9 years and 41.7 years in group 2. Group 1 had more comorbidity (p < 0.001). The most frequent indication for the procedure was obstructive jaundice in both groups (63% versus 44%; p = 0.002). Malignancy was more frequent as a cause of biliary obstruction in group 1 (45% versus 21%; p < 0.001). ERCP was performed once in 76% in group 1 and 93% in group 2 (p = 0.001). Prophylactic antibiotics were used more frequently in group 1 (84% versus 60%; p < 0.001). There were no differences between groups regarding infectious complications (p = 0.700). There was no difference in mortality rates between groups.


CONCLUSIONS
ERCP is a safe procedure in elderly patients. The elderly frequently have more comorbidity. Nevertheless, the complication and mortality rates did not differ in this study. It is noteworthy that elderly patients received prophylactic antibiotics more frequently than younger patients but infectious complications were not different. The patients should not be excluded from ERCP based on their age.
Avila-Funes
José Alberto
JA
Departments of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, Mexico City.
Montaño-Loza
Aldo
A
Zepeda-Gómez
Sergio
S
Meza-Junco
Judith
J
Melano-Carranza
Efrén
E
Valdovinos-Andraca
Francisco
F
Valdovinos-Díaz
Miguel A
MA
Ponce de León-Rosales
Sergio
S
D000328:Adult; D017677:Age Distribution; D000368:Aged; D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D015995:Prevalence